Lepodisiran vs SYH2068

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline

Lepodisiran

Developed by Eli Lilly and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05565742 · Phase 2 · completed

The trial randomized 320 participants and used double blinding with a placebo control. Its primary endpoint was a statistically significant reduction in Lp(a) versus placebo for all doses, but Lp(a) is a laboratory biomarker rather than a direct clinical outcome, so the findings provide moderate evidence.

Next expected readout: March 2027 · NCT07914738 (registry estimate)

Reported efficacy

Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) (met)

Result source: NCT05565742

SYH2068

Developed by CSPC Pharmaceutical Group

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT07640217 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLepodisiranSYH2068
LDL-C, % change—Trial running · NCT06292013—Not reported
Non-HDL-C, % change—Trial running · NCT06292013—Not reported
ApoB, % change-9.1% vs 4.3%−13.4 vs placebo400 mg · wk 77.14 · n 69NCT05565742
19 other results
  • -0.9% vs 4.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -10.4% vs 4.3% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -4.6% vs 4.3% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -14% vs 1.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -9% vs 1.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -0.6% vs 4.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -8.1% vs 4.3% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -13.8% vs 1.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -9.6% vs 1.3% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -11.8% vs 0.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • 1.4% vs 4.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -2.9% vs 4.3% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -7.6% vs 1.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -7% vs 1.3% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -10.2% vs 0.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
—Not reported
Lp(a), % change-74.4% vs 3.1%−77.5 vs placebo96 mg · n 74NCT05565742
25 other results
  • -39% vs 3.1% 16 mg · n 36 · Phase 2 · primary NCT05565742
  • -73.8% vs 1.3% 400 mg · wk 77.14 · n 69 · Phase 2 · secondary NCT05565742
  • -52.8% vs 1.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -91.1% vs -0.9% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -68.1% vs -0.9% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -96.8% vs -0.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -84.9% vs -0.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -95% vs 0.3% 400 mg · n 69 · Phase 2 · secondary NCT05565742
  • -76.7% vs 0.3% 400 mg · n 72 · Phase 2 · secondary NCT05565742
  • -45.1% vs 1.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -67.7% vs -0.9% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -84.8% vs -0.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -65.3% vs 2.2% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -80.4% vs 2.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • -77.4% vs 0.3% 96 mg · n 74 · Phase 2 · secondary NCT05565742
  • -18.7% vs 1.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -30.8% vs -0.9% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -47.7% vs -0.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -30.5% vs 2.2% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -46.2% vs 2.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
  • -38.7% vs 0.3% 16 mg · n 36 · Phase 2 · secondary NCT05565742
—Not reported
3-point MACE (% with event)—Trial running · NCT06292013—Not reported

LDL-C, % change

Lepodisiran
—Trial running · NCT06292013
SYH2068
—Not reported

Non-HDL-C, % change

Lepodisiran
—Trial running · NCT06292013
SYH2068
—Not reported

ApoB, % change

Lepodisiran
-9.1% vs 4.3%−13.4 vs placebo400 mg · wk 77.14 · n 69NCT05565742
19 other results
  • -0.9% vs 4.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -10.4% vs 4.3% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -4.6% vs 4.3% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -14% vs 1.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -9% vs 1.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -0.6% vs 4.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -8.1% vs 4.3% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -13.8% vs 1.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -9.6% vs 1.3% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -11.8% vs 0.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • 1.4% vs 4.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -2.9% vs 4.3% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -7.6% vs 1.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -7% vs 1.3% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -10.2% vs 0.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
SYH2068
—Not reported

Lp(a), % change

Lepodisiran
-74.4% vs 3.1%−77.5 vs placebo96 mg · n 74NCT05565742
25 other results
  • -39% vs 3.1% 16 mg · n 36 · Phase 2 · primary NCT05565742
  • -73.8% vs 1.3% 400 mg · wk 77.14 · n 69 · Phase 2 · secondary NCT05565742
  • -52.8% vs 1.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -91.1% vs -0.9% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -68.1% vs -0.9% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -96.8% vs -0.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -84.9% vs -0.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -95% vs 0.3% 400 mg · n 69 · Phase 2 · secondary NCT05565742
  • -76.7% vs 0.3% 400 mg · n 72 · Phase 2 · secondary NCT05565742
  • -45.1% vs 1.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -67.7% vs -0.9% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -84.8% vs -0.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -65.3% vs 2.2% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -80.4% vs 2.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • -77.4% vs 0.3% 96 mg · n 74 · Phase 2 · secondary NCT05565742
  • -18.7% vs 1.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -30.8% vs -0.9% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -47.7% vs -0.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -30.5% vs 2.2% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -46.2% vs 2.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
  • -38.7% vs 0.3% 16 mg · n 36 · Phase 2 · secondary NCT05565742
SYH2068
—Not reported

3-point MACE (% with event)

Lepodisiran
—Trial running · NCT06292013
SYH2068
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SYH2068: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lepodisiran: 3 of 4 rows · SYH2068: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLepodisiran
Dropout rate
2.9%400 mga
NCT05565742 · Phase 2
show 3 more results
2.8%400 mg
NCT05565742 · Phase 2
0%96 mg
NCT05565742 · Phase 2
2.8%16 mg
NCT05565742 · Phase 2
Discontinued due to AEs
—400 mga
NCT05565742 · Phase 2
show 3 more results
—400 mg
NCT05565742 · Phase 2
—96 mg
NCT05565742 · Phase 2
—16 mg
NCT05565742 · Phase 2
Serious AEs
15.9%400 mga
NCT05565742 · Phase 2
show 3 more results
11.1%400 mg
NCT05565742 · Phase 2
12.2%96 mg
NCT05565742 · Phase 2
2.8%16 mg
NCT05565742 · Phase 2
Most frequent reported AEs
400 mga
injection site reaction 11.6% (placebo 1.4%)
covid-19 7.2% (placebo 10.1%)
nasopharyngitis 7.2% (placebo 8.7%)
NCT05565742 · Phase 2
show 3 more results
400 mg
nasopharyngitis 13.9% (placebo 8.7%)
arthralgia 8.3% (placebo 2.9%)
injection site reaction 8.3% (placebo 1.4%)
NCT05565742 · Phase 2
96 mg
influenza 9.5% (placebo 2.9%)
injection site reaction 8.1% (placebo 1.4%)
nasopharyngitis 8.1% (placebo 8.7%)
NCT05565742 · Phase 2
16 mg
influenza 11.1% (placebo 2.9%)
ovarian cyst 11.1% (placebo 0%)
covid-19 5.6% (placebo 10.1%)
NCT05565742 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lepodisiran

Lp(a -95% (n=69) vs 0.3% (n=69) placebo400 mg
percent change · % of baseline
NCT05565742 · Phase 2
show 25 more results
-76.7% (n=72) vs 0.3% (n=69) placebo400 mg
NCT05565742 · Phase 2
-95.4% (n=69) vs 2.2% (n=69) placebo @ 8.57wk400 mg
NCT05565742 · Phase 2
-95.4% (n=72) vs 2.2% (n=69) placebo @ 8.57wk400 mg
NCT05565742 · Phase 2
-90.5% (n=69) vs 2.2% (n=69) placebo @ 25.71wk400 mg
NCT05565742 · Phase 2
-90.5% (n=72) vs 2.2% (n=69) placebo @ 25.71wk400 mg
NCT05565742 · Phase 2
-96.8% (n=69) vs -0.8% (n=69) placebo @ 34.29wk400 mg
NCT05565742 · Phase 2
-84.9% (n=72) vs -0.8% (n=69) placebo @ 34.29wk400 mg
NCT05565742 · Phase 2
-91.1% (n=69) vs -0.9% (n=69) placebo @ 51.43wk400 mg
NCT05565742 · Phase 2
-68.1% (n=72) vs -0.9% (n=69) placebo @ 51.43wk400 mg
NCT05565742 · Phase 2
-73.8% (n=69) vs 1.3% (n=69) placebo @ 77.14wk400 mg
NCT05565742 · Phase 2
-52.8% (n=72) vs 1.3% (n=69) placebo @ 77.14wk400 mg
NCT05565742 · Phase 2
-74.4% (n=74) vs 3.1% (n=69) placebo96 mg
NCT05565742 · Phase 2
-77.4% (n=74) vs 0.3% (n=69) placebo96 mg
NCT05565742 · Phase 2
-80.4% (n=74) vs 2.2% (n=69) placebo @ 8.57wk96 mg
NCT05565742 · Phase 2
-65.3% (n=74) vs 2.2% (n=69) placebo @ 25.71wk96 mg
NCT05565742 · Phase 2
-84.8% (n=74) vs -0.8% (n=69) placebo @ 34.29wk96 mg
NCT05565742 · Phase 2
-67.7% (n=74) vs -0.9% (n=69) placebo @ 51.43wk96 mg
NCT05565742 · Phase 2
-45.1% (n=74) vs 1.3% (n=69) placebo @ 77.14wk96 mg
NCT05565742 · Phase 2
-39% (n=36) vs 3.1% (n=69) placebo16 mg
NCT05565742 · Phase 2
-38.7% (n=36) vs 0.3% (n=69) placebo16 mg
NCT05565742 · Phase 2
-46.2% (n=36) vs 2.2% (n=69) placebo @ 8.57wk16 mg
NCT05565742 · Phase 2
-30.5% (n=36) vs 2.2% (n=69) placebo @ 25.71wk16 mg
NCT05565742 · Phase 2
-47.7% (n=36) vs -0.8% (n=69) placebo @ 34.29wk16 mg
NCT05565742 · Phase 2
-30.8% (n=36) vs -0.9% (n=69) placebo @ 51.43wk16 mg
NCT05565742 · Phase 2
-18.7% (n=36) vs 1.3% (n=69) placebo @ 77.14wk16 mg
NCT05565742 · Phase 2
Apo B -13.9% (n=69) vs 0.2% (n=69) placebo @ 8.57wk400 mg
percent change · % of baseline
NCT05565742 · Phase 2
show 19 more results
-13.9% (n=72) vs 0.2% (n=69) placebo @ 8.57wk400 mg
NCT05565742 · Phase 2
-12.6% (n=69) vs 1.3% (n=69) placebo @ 25.71wk400 mg
NCT05565742 · Phase 2
-12.6% (n=72) vs 1.3% (n=69) placebo @ 25.71wk400 mg
NCT05565742 · Phase 2
-14% (n=69) vs 1.8% (n=69) placebo @ 34.29wk400 mg
NCT05565742 · Phase 2
-9% (n=72) vs 1.8% (n=69) placebo @ 34.29wk400 mg
NCT05565742 · Phase 2
-10.4% (n=69) vs 4.3% (n=69) placebo @ 51.43wk400 mg
NCT05565742 · Phase 2
-4.6% (n=72) vs 4.3% (n=69) placebo @ 51.43wk400 mg
NCT05565742 · Phase 2
-9.1% (n=69) vs 4.3% (n=69) placebo @ 77.14wk400 mg
NCT05565742 · Phase 2
-0.9% (n=72) vs 4.3% (n=69) placebo @ 77.14wk400 mg
NCT05565742 · Phase 2
-11.8% (n=74) vs 0.2% (n=69) placebo @ 8.57wk96 mg
NCT05565742 · Phase 2
-9.6% (n=74) vs 1.3% (n=69) placebo @ 25.71wk96 mg
NCT05565742 · Phase 2
-13.8% (n=74) vs 1.8% (n=69) placebo @ 34.29wk96 mg
NCT05565742 · Phase 2
-8.1% (n=74) vs 4.3% (n=69) placebo @ 51.43wk96 mg
NCT05565742 · Phase 2
-0.6% (n=74) vs 4.3% (n=69) placebo @ 77.14wk96 mg
NCT05565742 · Phase 2
-10.2% (n=36) vs 0.2% (n=69) placebo @ 8.57wk16 mg
NCT05565742 · Phase 2
-7% (n=36) vs 1.3% (n=69) placebo @ 25.71wk16 mg
NCT05565742 · Phase 2
-7.6% (n=36) vs 1.8% (n=69) placebo @ 34.29wk16 mg
NCT05565742 · Phase 2
-2.9% (n=36) vs 4.3% (n=69) placebo @ 51.43wk16 mg
NCT05565742 · Phase 2
1.4% (n=36) vs 4.3% (n=69) placebo @ 77.14wk16 mg
NCT05565742 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lepodisiran's landscape · SYH2068's landscape